Quantitative proteomic analysis of lymphoma transformation

淋巴瘤转化的定量蛋白质组分析

基本信息

批准号：
7254275
负责人：
KOJO S. J. ELENITOBA-JOHNSON
金额：
$ 28.03万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-07-01 至 2009-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7254275
关键词：
3-Dimensional Accounting Adult Agreement Algorithms Antibodies Anus Appendix Archives B-Cell Lymphomas Bayesian Analysis Behavior Therapy Bibliography Bioinformatics Biological Biological Assay Biology Biometry Biopsy Budgets Cancer Center Cataloging Catalogs Categories Cell physiology Cells Certification Class Classification Classification Scheme Clinical Data Clonality Cohort Studies Collaborations Computer software Coupled DNA Data Development Diagnosis Diagnostic Diffuse Diffuse Lymphoma Digestion Direct Costs Discrimination Disease Drops Early Diagnosis Elements Emerging Technologies Endopeptidases Ensure Enzymes Evaluation Event Experimental Designs Figs - dietary Follicular Lymphoma Freezing Funding Generic Drugs Genome Goals Grant Healthcare Systems Hematology High Performance Computing Histologic Human Resources Immunohistochemistry Indium Individual Indolent Clinical Course Institution Investigation Laboratories Lead Light Lymphoma MAPK14 gene Malignant Neoplasms Mass Spectrum Analysis Matched-Pair Analysis Methodology Methods Minor Molecular Genetics Molecular Profiling NIH Program Announcements Neoplasms Nomenclature Non-Hodgkin&apos s Lymphoma Numbers Pathogenesis Pathologist Pathology Pathway interactions Patients Pattern Peptide Hydrolases Peptides Performance Phosphoproteins Polymerase Chain Reaction Process Protein Analysis Protein Deregulation Proteins Proteolysis Proteome Proteomics Published Comment Publishing Recommendation Reliance Research Design Research Personnel Resources Reverse Transcriptase Polymerase Chain Reaction Reverse Transcription Sampling Sorting - Cell Movement Source Specificity Specimen Subgroup Suspension substance Suspensions System Taxonomy Techniques Technology Therapeutic Time Tissues Treatment Protocols Trypsin Universities Utah Validation Variant Western Blotting Work anticancer research base cancer therapy cohort design glutamyl endopeptidase insight interest large cell Diffuse non-Hodgkin&apos s lymphoma mortality neoplastic novel numb protein parallel computing peptidyl-Lys metalloendopeptidase prognostic programs protein expression response size tandem mass spectrometry technology development tumor

项目摘要

DESCRIPTION (provided by applicant): Non-Hodgkin's lymphoma accounts for approximately 50,000 new cases of cancer annually. This figure represents an increase beyond that seen for most other forms of cancer. Among the non-Hodgkin's lymphomas, follicular lymphoma represents the most common subtype of low-grade B-cell lymphoma in adults, and typically pursues an indolent clinical course. In a significant proportion of cases there is histologic transformation from a low-grade neoplasm to an aggressive diffuse large B-cell lymphoma with significantly decreased median survival. The recent advent of sophisticated mass spectrometry technology coupled with software algorithms that permit instantaneous protein identification, makes it feasible to study the pattern of protein deregulation that distinguish two biologic states. We propose to employ a combination of chromatographic techniques and tandem mass spectrometry in the identification of the alterations in protein expression that accompany histologic transformation. We shall be analyzing a cohort of matched pairs of follicular lymphoma and their transformed diffuse large B-cell lymphoma counterparts occurring in the same individual. Relevance: Comprehensive identification of the qualitative and quantitative changes in protein expression that are involved in follicular lymphoma transformation will permit the delineation of deregulated pathways, identify distinct prognostic subgroups of transformed lymphoma, and facilitate the development of novel therapies that target susceptible elements in the deregulated pathways.

描述（由申请人提供）：非霍奇金淋巴瘤每年约造成 50,000 例新发癌症病例。这个数字代表了超过大多数其他形式癌症的增长。在非霍奇金淋巴瘤中，滤泡性淋巴瘤是成人低度 B 细胞淋巴瘤最常见的亚型，通常呈惰性临床病程。在很大一部分病例中，组织学发生从低度肿瘤转变为侵袭性弥漫性大 B 细胞淋巴瘤，中位生存期显着降低。最近出现的复杂质谱技术与允许即时蛋白质识别的软件算法相结合，使得研究区分两种生物状态的蛋白质失调模式成为可能。我们建议结合使用色谱技术和串联质谱来鉴定伴随组织学转化的蛋白质表达的改变。我们将分析同一个体中发生的一组匹配的滤泡性淋巴瘤及其转化的弥漫性大 B 细胞淋巴瘤对应物。相关性：全面鉴定滤泡性淋巴瘤转化中涉及的蛋白质表达的定性和定量变化将允许描绘解除管制的途径，识别转化淋巴瘤的不同预后亚组，并促进针对解除管制中的敏感元件的新疗法的开发途径。